Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Merck & Co's earlier efforts to find new therapies for Alzheimer's disease resulted in failure, but the company is returning to the field via an R&D alliance with UK biotech Cerevance that will ...

Merck’s diabetes drugs – Januvia and Janumet – are likely to see increased competition. The company’s animal health business is likely to benefit from increased pet ownership in the U.S ...

Eisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Merck & Co’s Belsomra ... such as drowsiness, memory problems and a risk of falling, than ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Jan. 15, 2025 — Regular aerobic exercise could significantly reduce disease markers associated with Alzheimer's, new research has found. The findings provide new hope in the battle against this ...

Jan. 15, 2025 — Regular aerobic exercise could significantly reduce disease markers associated with Alzheimer's, new research has found. The findings provide new hope in the battle against this ...

Dementia cases in the U.S. are expected to double by 2060 when around 1 million Americans are projected to develop the memory ...

was originally picked up via Merck’s $11.5 billion acquisition of Acceleron back in 2021. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Winrevair in ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

After hours: January 17 at 7:59:38 PM EST Loading Chart for MRK ...

In this article, we are going to take a look at where Merck & Co., Inc ... particularly with GLP-1 drugs, which have the potential to treat more conditions beyond diabetes and weight loss.